Notices. Notice
415 words·~2 min read·
/register/2002/01/03/02-12A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4140-01-M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Co-Exclusive License: “cDNA for Human and Pig Dihydropyrimidine Dehydrogenase' AGENCY: National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an co-exclusive license to practice the inventions embodied in U.S.
Patents 5,856,454 and 6,015,673, entitled “cDNA for Human and Pig Dihydropyrimidine Dehydrogenase” to Variagenics, Inc. of Cambridge, MA. The prospective co-exclusive license territory will be worldwide and the field of use may be limited to *in vitro* diagnostics. DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before March 4, 2002 will be considered. ADDRESSES: Requests for copies of the patents, inquiries, comments, and other materials relating to the contemplated co-exclusive license should be directed to:
Matthew B. Kiser, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone:
(301)496-7056 x224; Facsimile
(301)402-0220; E-mail kiserm@od.nih.gov. SUPPLEMENTARY INFORMATION: The technology relates to the DPD gene. Cancer patients having a DPD deficiency are at risk of a severe toxic reaction to the commonly used anticancer agent 5-fluorouracil (5-FU). Claimed are DPD genes from human and pig, methods for detecting the level of nucleic acids that encode DPD in patient, and nucleic acids that are useful as probes for this purpose. The prospective co-exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective co-exclusive license may be granted unless within sixty
(60)days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated co-exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: December 20, 2001. Jack Spiegel, Director, Division of Technology Development and Transfer, Office of Technology Transfer. [FR Doc. 02-12 Filed 1-2-02; 8:45 am]
Connectionstraces to 3
Citation graph
cites case law
Cites 3Cited by 0 across 0 sources